Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 14 von 160

Details

Autor(en) / Beteiligte
Titel
402-P: Comparison of the Effects of Sodium–Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes
Ist Teil von
  • Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)
Ort / Verlag
New York: American Diabetes Association
Erscheinungsjahr
2020
Quelle
EZB Electronic Journals Library
Beschreibungen/Notizen
  • Background: Influential guidelines recommend using SGLT2i preferentially among antidiabetic drugs in patients with diabetes and ASCVD. Although CVOTs with SGLT2i showed reduction in risk of 3-point major adverse cardiovascular events (MACE), they did not demonstrate beneficial effect on stroke. In addition, a meta-analysis reported adverse effect of SGLT2i for stroke. On the contrary, pioglitazone, a type of TZD, demonstrated the effect in secondary stroke prevention from two large RCTs. The aim of this study was to compare the effect of SGLT2i and TZD on the risk of stroke among patients with type 2 diabetes. Methods: Using the Korean National Health Insurance Service data, we compared a 1:1 propensity score-matched cohort of patients who were new users of SGLT2i (n = 82,044) and TZD (n = 82,044) from January 2014 to December 2018. The primary outcome was stroke. The secondary outcomes were MI, CV death, and 3-point MACE. Results: The incidence rates of stroke were 5.2 and 5.3 per 1000 person-years in SGLT2i-treated patients and TZD-treated patients, respectively. The hazard ratio of stroke was 0.955 (95% CI: 0.841-1.084) in SGLT2i-treated patients compared with TZD-treated patients. There was no clear difference in risk of MI (HR: 1.151, 95% CI: 0.914-1.449), CV death (HR: 0.865, 95% CI: 0.660-1.132), 3-point mace (HR: 0.988, 95% CI: 0.894-1.092) between two groups. Results were consistent regardless of prior CV disease. Conclusions: In this real-world data, the risk of stroke was comparable in patients with type 2 diabetes treated with TZD vs. SGLT2i. Disclosure S. Lee: None. H. Nam: None. H. Choi: None. K. Kim: None.
Sprache
Englisch
Identifikatoren
ISSN: 0012-1797
eISSN: 1939-327X
DOI: 10.2337/db20-402-P
Titel-ID: cdi_proquest_journals_2419454308

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX